AstraZeneca announces talk for note sale in seven-, 30-year tranches

By Andrea Heisinger

New York, Sept. 11 - AstraZeneca plc is set to price notes due 2019 and 2042 in a sale announced on Tuesday, according to a filing with the Securities and Exchange Commission.

The notes (A1/AA-/) are being priced to repay outstanding debt and for general corporate purposes.

The seven-year notes are talked in the 95 basis points area, while the 30-year tranche has guidance in the 120 bps area.

Goldman Sachs & Co., HSBC Securities (USA) LLC, J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC are running the books.

The biopharmaceutical company is based in London.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.